GRFS - Grifols, S.A.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.28
+0.30 (+1.58%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close18.98
Open19.08
Bid17.00 x 800
Ask68.01 x 800
Day's Range18.95 - 19.28
52 Week Range17.42 - 24.97
Volume200,784
Avg. Volume820,363
Market Cap16.351B
Beta (3Y Monthly)0.82
PE Ratio (TTM)32.16
EPS (TTM)0.60
Earnings DateN/A
Forward Dividend & Yield0.46 (2.31%)
Ex-Dividend Date2018-11-30
1y Target Est21.75
Trade prices are not sourced from all markets
  • Grifols PharmacyKeeper Receives KLAS Category Leader Award for Third Consecutive Year
    PR Newswire3 days ago

    Grifols PharmacyKeeper Receives KLAS Category Leader Award for Third Consecutive Year

    This marks the third consecutive year the PharmacyKeeper Verification software has been recognized as the leader in the IV Workflow Management category by KLAS Research, a healthcare IT data and insight-gathering company that collects and publishes impartial research on the software and services used by healthcare providers and payers worldwide. The PharmacyKeeper suite of software applications was developed by MedKeeper, which was acquired by Grifols in January, 2018.

  • 'Young blood' Alzheimer's treatments slapped with warning by FDA commissioner
    American City Business Journals4 days ago

    'Young blood' Alzheimer's treatments slapped with warning by FDA commissioner

    After the FDA warned about "young blood" purporting to treat a range of diseases, including Alzheimer's and post-traumatic stress disorder, a company with a clinical operation in San Francisco has ceased its treatments.

  • East Bay biotech with late-stage drug files for bankruptcy
    American City Business Journals4 days ago

    East Bay biotech with late-stage drug files for bankruptcy

    Over 28 years, the company spent a half-billion dollars on developing inhaled lung-disease drugs that fell short of FDA approval.

  • Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System
    PR Newswire16 days ago

    Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System

    BARCELONA, Spain, Feb. 7, 2019 /PRNewswire/ -- Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the U.S. Food and Drug Administration (FDA) approved the Procleix Babesia assay, a qualitative assay for the detection of the ribosomal RNA from 4  Babesia species (B. microti, B. duncani, B. divergens, B. venatorum) in individual samples or up to 16 pooled lysed specimens from human donors, including donors of whole blood and blood components for transfusion.

  • What To Know Before Buying Grifols, S.A. (BME:GRF) For Its Dividend
    Simply Wall St.19 days ago

    What To Know Before Buying Grifols, S.A. (BME:GRF) For Its Dividend

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Dividends play an important role in compounding Read More...

  • Benzingalast month

    Rigel Rises On European Marketing Agreement For Autoimmune Drug

    Small-cap biotech Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL )'s shares were advancing Wednesday after it announced an agreement to commercialize fostamatinib, its autoimmune disorder drug. What Happened ...

  • MarketWatchlast month

    Rigel Pharmaceuticals stock up 9% after announcing licensing agreement with Grifols

    Shares of Rigel Pharmaceuticals Inc. shot up 9% in premarket trade Wednesday after the company announced it had entered a license and supply agreement with Spain-based Grifols, S.A. to commercialize fostamatinib disodium hexahydrate, its treatment for thrombocytopenia in adult patients. It is commercially available in the U.S. under the brand name Tavalisse. Under the terms of the agreement, Rigel will receive a $30 million upfront cash payment, with a potential $297.5 million in payments upon reaching certain regulatory and commercial milestones. That figure includes a potential $20 million payment upon the European Medicines Agency approving fostamatinib for the treatment of chronic idiopathic thrombocytopenic purpura (ITP). Rigel will also receive royalty payments based on tiered net sales, which the company said could reach 30% of net sales. In return, Grifols will receive exclusive rights to fostamatinib in Europe and Turkey. However, if fostamatinib has not been approved by the EMA for the treatment of ITP by 2021, Grifols will have the option to terminate the entire agreement, the companies said, and Rigel will have to pay Grifols $25 million to regain all rights to fostamatinib in Europe and Turkey. Rigel shares have fallen 12% in the year to date through Tuesday, while the iShares Nasdaq Biotechnology ETF has gained 12.7%. The S&P 500 has gained 5%.

  • Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
    PR Newswirelast month

    Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

    - Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey - Rigel to receive an upfront payment of $30 million , with the potential for $297.5 million in total ...

  • Grifols receives FDA approval of Erytra Eflexis®, the latest advancement in scalable blood typing solutions
    PR Newswire2 months ago

    Grifols receives FDA approval of Erytra Eflexis®, the latest advancement in scalable blood typing solutions

    - Erytra Eflexis is a fully automated, benchtop analyzer that performs pretransfusion compatibility testing - This system incorporates two laboratory configurations in a single instrument, providing laboratory ...

  • A Note On Grifols, S.A.’s (BME:GRF) ROE and Debt To Equity
    Simply Wall St.2 months ago

    A Note On Grifols, S.A.’s (BME:GRF) ROE and Debt To Equity

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...

  • A Look At The Fair Value Of Grifols SA (BME:GRF)
    Simply Wall St.3 months ago

    A Look At The Fair Value Of Grifols SA (BME:GRF)

    I am going to run you through how I calculated the intrinsic value of Grifols SA (BME:GRF) by taking the foreast future cash flows of the company and discounting them Read More...

  • Reuters3 months ago

    Shanghai RAAS in tie-up talks with U.S. blood products arm of Spain's Grifols

    China's Shanghai RAAS Blood Products Co Ltd is in talks to combine with a U.S. subsidiary of Spanish blood products company Grifols, the two companies said. Grifols said the talks could lead to it exchanging Grifols Diagnostic Solutions Inc, which it said was valued at around $5 billion, for newly-issued Shanghai RAAS shares. Grifols would have strategic direction of the business.

  • Reuters3 months ago

    BRIEF-Shanghai RAAS Blood Products Plans To Acquire Tiancheng (Germany), Spain's Grifols Diagnostic Solutions

    Nov 22 (Reuters) - Shanghai RAAS Blood Products Co Ltd : * SAYS IT PLANS TO BUY TIANCHENG (GERMANY), WHICH OWNS ABOUT 90 PERCENT OF BIOTEST AG, FOR 589 MILLION EUROS (NOT TO BUY GERMANY'S BIOTEST FOR 589 ...

  • Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol
    PR Newswire4 months ago

    Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol

    - AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma science has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate AD patients. BARCELONA, Spain, Oct. 27, 2018 /PRNewswire/ -- Presenting the study results, Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program confirmed that the analysis of AMBAR data in moderate patients has shown positive, highly relevant results in a cohort of patients suffering from moderate Alzheimer's disease.

  • FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing
    PR Newswire4 months ago

    FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing

    Test Offers Shortest Time to Reportable Results For US Hospitals, Reference Labs and Blood Centers - Efficient system analyzes 37 antigens of 10 blood group systems - Helps minimize allo-immunization risk ...

  • Grifols (GRFS) Surges: Stock Moves 5.4% Higher
    Zacks4 months ago

    Grifols (GRFS) Surges: Stock Moves 5.4% Higher

    Grifols (GRFS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • PR Newswire5 months ago

    Grifols Delivers Promise of Advancing Plasma-derived Medicines through Innovative Vision and Donor Support

    - Plasma-derived medicines replace missing or deficient proteins with healthy proteins that are obtained through human plasma donations. - Grifols' continued commitment to patients is evidenced by the expansion of its plasma donor center network and innovations for treatments of serious, rare and life-threatening illnesses. - Grifols is conducting clinical research on Alzheimer's disease.

  • Reuters5 months ago

    Italian stocks lead Europe as budget deficit fears quelled

    Italian stocks turned from a drag into a boost for European markets on Wednesday as signs the government would target a lower budget deficit quelled investors' fears of a damaging showdown with the European Commission. Italy's FTSE MIB outperformed and closed up 0.9 percent while the leading euro zone stocks index and the pan-European STOXX 600 climbed 0.8 percent and 0.6 percent respectively.

  • PR Newswire5 months ago

    Grifols Announces the Opening of Biotest Pharmaceuticals Corporation's Newest Plasma Donor Center in Bowling Green, Ohio

    BOWLING GREEN, Ohio, Sept. 24, 2018 /PRNewswire/ -- Grifols is pleased to announce the opening of its newest Biotest Pharmaceuticals Corporation (BPC) plasma donor center located at 1616 East Wooster Street, Bowling Green, Ohio.

  • Is Grifols, S.A. (GRFS) a Great Stock for Value Investors?
    Zacks5 months ago

    Is Grifols, S.A. (GRFS) a Great Stock for Value Investors?

    Is Grifols, S.A. (GRFS) a great pick from the value investor's perspective right now? Read on to know more.

  • Who Owns Grifols SA (BME:GRF)?
    Simply Wall St.5 months ago

    Who Owns Grifols SA (BME:GRF)?

    A look at the shareholders of Grifols SA (BME:GRF) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owningRead More...

  • Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins
    PR Newswire6 months ago

    Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins

    Additional submissions to the FDA are planned to relocate the production of other licensed recombinant protein products. The transition is targeted for completion in mid-2019, pending the FDA approvals for the licensed antigens. Once the transition is complete, Grifols will have transferred 21 products to CMF.

  • Procleix® Zika Virus Assay Approved by the FDA for Blood Screening on the Procleix® Panther® System
    PR Newswire6 months ago

    Procleix® Zika Virus Assay Approved by the FDA for Blood Screening on the Procleix® Panther® System

    - Procleix Zika Virus assay approved for the detection of viral RNA in plasma and serum specimens, previously used since June 2016 under IND protocol - Procleix Zika Virus assay provides U.S. blood banks ...